Publications

Abstracts

  1. Roy V, Clink HM, Ernst P, Spence DG, Padmos MA.  Intra-vesical prostaglandin instillation for the treatment of severe hemorrhagic cystitis in bone marrow transplant patients. Blood. 1990; 76(10 Suppl 1):2236.
  2. Roy V, Verfaillie C.  Refractory thrombocytopenia due to PLA1 antibodies following autologous peripheral blood stem cell transplantation (Abstract 1940).  Blood. 1994 Nov 15; 84(10 Suppl 1):489a.
  3. Roy V, Verfaillie C.  Human fetal liver hematopoietic "stem cells" have a higher proliferative potential and exhibit different phenotypic characteristics than adult bone marrow or umbilical cord blood "stem cells".  J Investig Med. 1995 Apr; 43(Suppl 2):342A.
  4. Roy V, Verfaillie CM.  Phenotypic and functional characterization of human fetal liver progenitors (Abstract 2355).  Blood. 1995 Nov 15; 86(10 Suppl 1):592a.
  5. Roy V, Wiedorf DJ.  Mycobacterial infections following bone marrow transplant (BMT): A 20 year retrospective review of 20 year experience (Abstract 861).  Blood. 1995 Nov 15;86(10 Suppl 1):218a.
  6. Roy V, Verfaillie C.  Soluble factor(s) produced by adult bone marrow stroma inhibit fetal liver BFU-E (Abstract 14).  Exp Hematol. 1996 Aug; 24(9):1027.
  7. Roy V, Verfaillie CM.  Differences in cell adhesion molecule expression and adhesive properties of adult marrow, cord blood and fetal liver CD34+ cells (Abstract 2231). Blood. 1996 Nov 15; 88(10 Suppl 1):536a.
  8. Mandanas RA, Saez RA, Selby GB, Roy V, Confer DL. G-CSF mobilized donor leukocyte infusions as immunotherapy for acute leukemia in relapse after allogeneic bone marrow transplantation (BMT) (Abstract 4465).  Blood. 1997 Nov 15; 90(10 Suppl 1):382b.
  9. Roy V, Mandanas RA, Watkins C, Carter T, Selby GB.  Mobilized peripheral blood stem cell transplantation in out-patient setting: limitations to applicability in an unselected patient population (Abstract 1713).  Blood. 1997 Nov 15; 90(10 Suppl 1):385a.
  10. Roy V, Verfaillie CM.  Integrin expression and function on fetal liver hematopoietic progenitors: alpha 2 beta 1 integrin mediated adhesion to collagen type-IV, and inhibition of fetal liver CFC proliferation (Abstract 2157).  Blood. 1997 Nov 15; 90(10 Suppl 1):485a.
  11. Roy V, Watkins C, Mandanas RA, Selby GB. Transient early rise in absolute neutrophil counts after high-dose chemotherapy and autologous PBSC infusion predicts rapid hematopoietic reconstitution (Abstract 4410).  Blood. 1998 Nov 15; 92(10 Suppl 1):327b.
  12. Rizvi MA, Vesely SK, Roy V, George JN. Thrombotic thrombocytopenic purpura- hemolytic uremic syndrome (TTP-HUS) following bone marrow transplantation (BMT): risk-factors and outcomes (Abstract 58). Blood. 1999 Nov 15; 94(10 Suppl 1):16a-17a.
  13. Roy V, Ali LI, Mandanas RA, Carter TH, Selby GB.  Successful non-surgical treatment of disseminated polymicrobial fungal infection of lungs and brain in a patient with pancytopenia and GVHD (Abstract 4887).  Blood. 1999 Nov 15; 94(10 Suppl 1):371b.
  14. Roy V, Mandanas RA, Carter TH, Selby GB.  Randomized comparison of two G-CSF schedules for peripheral blood progenitor cell mobilization in high-risk breast cancer patients (Abstract 1459).  Blood. 1999 Nov 15; 94(10 Suppl 1):326a.
  15. Litzow MR, Hogan WJ, Micallef IN, Dispenzieri A, Gertz MA, Inwards DJ, Tun HW, Roy V, Geyer SM, Allred JB, Ansell SM, Elliott MA, Tefferi A, Porrata LF, Gastineau DA, Lacy MQ.  A phase I/II trial of cladribine (2-CDA), thiotepa (TT) and rabbit antithymocyte globulin (rATG) as a reduced intensity conditioning (RIC) regimen for non-myeloablative allogeneic peripheral blood stem cell transplant (NMA-PBSCT) for hematologic malignancies. Blood. 2003 Nov 16; 102(11):402b.
  16. Roy V, Perez WS, Marsh J, Pasquini R, Eapen M, Bredeson C.  Bone marrow transplantation for Diamond-Blackfan Anemia: Report of the international bone marrow transplant registry experience.  Blood. 2003 Nov 16; 102(11):245a.
  17. Zubair A, Grant R, Black N, Bertholf M, Roy A, Roy V.  Severe acute hemolytic transfusion reaction following ABO-mismatched platelet transfusion: Should ABO- mismatched platelet transfusion policy be evaluated.  Blood. 2004 Nov 16; 104(11 Part 1):110B.
  18. Baweja M, Moreno-Aspitia A, Menke DM, Roy V, Zubair A.  Marked elliptocytosis in myelodysplastic syndromes (MDS) is associated to deletion of chromosome 20q (Abstract 4927).  Blood. 2005 Nov; 106(11):311b-312b.
  19. Zubair A, Grant R, Tun H, Rivera C, Moreno-Aspitia A, Roy V, Colon-Otero G, Solberg L. Platelet count is a sensitive predictor of bone marrow reserve and autologous peripheral blood progenitor cell mobilization (Abstract 5280).  Blood. 2005 Nov; 106(11):404b.
  20. Amar S, Sekhon SS, Roy V. Autologous hemopoietic stem cell transplantation is a viable treatment option for post liver transplant lymphoproliferative disorder: a case report (Abstract 5447). Blood. 2006 Nov; 108(11 part 2):457b.
  21. Roy V, Bersagel PL, Allred J, Greipp PR.  Melphalan (M), prednisone (P) and lenalidomide (R) combination (MPR) for newly diagnosed multiple myeloma patients who are not candidates for stem cell transplantation (Abstract 3558).  Blood. 2006 Nov; 108(11 part 1):1016a.
  22. Roy V, LaPlant B, Gross G, Palmieri F, Perez E. NCCTG phase II trial N0531of weekly nab-paclitaxel (nab-p) in combination with gemcitabine (gem) in patients with metastatic breast cancer (MBC) J Clin Oncol. 2007 Jun 20; 25(18s):44s. Abstract no. 1048.
  23. Johnston PB, Ansell SM, Colgan JP, Habermann TM, Inwards DJ, Markovic SN, Micallef INM, Porrata LF, Reeder CB, Roy V, LaPlant BR, Witzig TE.  Promising results for patients with relapsed or refractory Hodgkin lymphoma treated with the oral mtor  inhibitor everolimus (RAD001).  Haematologica-the Hematology Journal. 2007 Nov; 92(Suppl 5):29.
  24. Johnston PB, Ansell SM, Colgan JP, Habermann TM, Inwards DJ, Micallef LNM, Porrata LF, Reeder CB, Roy V, LaPlant BR, Witzig TE.  mTOR inhibition for relapsed or refractory Hodgkin lymphoma: Promising single agent activity with Everolimus  (RAD001).  Blood. 2007 Nov; 110(11):753A.
  25. Johnston PB, Ansell S, Colgan J, Habermann T, Inwards D, Markovic S, Micallef I, Porrata L, Reeder C, Roy V, LaPlant B, Witzig T.  Oral MTOR inhibition with everolimus in relapsed T cell and Hodgkin lymphoma.  Ann Oncol. 2008 Jun; 19(Suppl 4):162.
  26. SImpron L, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman S, Roy V, Stewart K, Gertz MA, Greipp PA, Kumar S. High incidence of diarrhea in patients on long term therapy with lenalidomide and dexamethasone for multiple myeloma. J Clin Oncol 26: 2008 (May 20 suppl; abstr 8586.
  27. Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, Dispenzieri A, Buadi F, Bergsagel PL, Gertz M, Dalton R, Mikhael J, Dingli D, Reeder CB, Lust JA, Russell S, Roy V, Zeldenrust SR, Stewart K, Kyle RA, Greipp PR, Rajkumar SV.  Survival in patients with newly diagnosed myeloma undergoing therapy with lenalidomide and dexamethasone: impact of high-risk cytogenetic risk status on outcome.  Blood. 2008 Nov; 112(11):42-3.
  28. Lacy MQ, Hayman SR, Gertz MA, Allred JB, Mandrekar SJ, Dispenzieri A, Zeldenrust SR, Kumar S, Greipp PR, Lust JA, Russell SJ, Buadi F, Kyle RA, Bergsagel PL, Fonseca R, Roy V, Mikhael J, Stewart AK, Rajkumar SV.  Pomalidomide (CC4047) plus low-dose dexamethasone (Pom/dex) is highly effective therapy in relapsed multiple myeloma.  Blood. 2008 Nov; 112(11):320.
  29. Roy V, Stewart AK, Bergsagel PL, Dispenzieri A, Laumann K, Allred J, Lacy MQ, Fonseca R, Reeder CB, Kumar S, Rivera CE, Gertz MA, Greipp PR, Buadi FK, Hayman SR, Rajkumar SV.  Phase II study of melphalan, prednisone and lenalidomide combination for newly diagnosed multiple myeloma patients who are not candidates for stem cell transplantation.  Blood. 2008 Nov; 112(11):955.
  30. Pockaj BA, Mukherjee P, Tinder TL, Klosterman CA, Allerd JB, Roy V, Perez EA. NCCTG N0338: effect of docetaxel and carboplatin on VEGF, PGE(2), and immune cells in patients with stage II or III breast cancer.  Cancer Res. 2009 Jan; 69(2 Suppl S):333S- 4S.
  31. Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Zeldenrust SR, Kumar S, Greipp PR, Lust JA, Russell SJ, Buadi F, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Allred JB, Laumann K, Thompson M, Mandrekar SJ, Rajkumar SV, Dingli D, Reeder C. Pomalidomide (CC4047) plus low-dose dexamethasone (pom/dex) as  therapy for relapsed multiple myeloma.  Clin Lymphoma Myeloma. 2009 Feb; 9(Suppl 2):S46-7.
  32. Apsey H, Roy V, Pockaj B, Northfelt D, Sticca R, Nikcevich DA, Mattar B, Fitch T, Perez EA.  Surgical practice patterns following NCCTG N0338 "Phase II trial of docetaxel and darboplatin administered every two weeks as induction therapy for stage II and stage III breast cancer.".  J Clin Oncol. 2009 May 20; 27(15s). Abstract no. 623.
  33. Sukov WR, Miller DV, Dueck AC, Tenner KS, Jenkins RB, Kaufman PA, Davidson NE, Dakhil SR, Martino S, Roy V, Perez EA.  Benefit of adjuvant trastuzumab in breast cancer patients with focal HER2 amplified clones: Data from N9831 Intergroup Adjuvant Trial. J Clin Oncol. 2009 May 20; 27(Suppl S):520.
  34. Dispenzieri A, Gertz MA, Hayman SR, Buadi F, Kumar S, Reeder CB, Zeldenrust SR, Rajkumar SV, Detweiler-Short K, Lust JA, Witzig TE, Greipp PR, Russell SJ, Dingli D, Allred J, Laumann K, Thompson MA, Fonseca R, Stewart AK, Bergsagel PL, Mikhael JR, Roy V, Kyle R, Lacy MQ. A pilot study of pomalidomide and dexamethasone in previously treated light chain amyloidosis patients.  Blood. 2009 Nov 20; 114(22):1482-3.
  35. Gay F, Rajkumar SV, Falco P, Kumar S, Dispenzieri A, Gertz M, Di Raimondo F, Lacy MQ, Crippa C, Buadi F, Falcone A, Hayman SR, Giuliani N, Short KED, Musto P, Roy V, Corradini P, Fonseca R, Petrucci MT, Greipp PR, Boccadoro M, Stewart AK, Palumbo A. Lenalidomide plus dexamethasone versus lenalidomide plus melphalan and prednisone: a case-control study in newly diagnosed elderly myeloma patients.  Blood. 2009 Nov 20; 114(22):1123.
  36. Gay F, Rajkumar SV, Jayabalan DS, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard JP, Lacy MQ, Chen-Kiang S, Roy V, Coleman M, Hayman SR, Buadi F, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Niesvizky R. Clarithromycin (biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (RD) as initial therapy for newly diagnosed multiple myeloma.  Blood. 2009 Nov 20; 114(22):1119-20.
  37. Kumar S, Hayman SR, Buadi F, Allred J, Laumann K, Roy V, Lacy MQ, Gertz MA, Detweiler K, Birgin A, Bergsagel L, Dingli D, Mikhael JR, Reeder CB, Stewart K, Zeldenrust SR, Rajkumar V, Dispenzieri A.  A phase II trial of lenalidomide, cyclophosphamide and dexamethasone (RCD) in patients with light chain amyloidosis. Blood. 2009 Nov 20; 114(22):1482.
  38. Lacy MQ, Gertz MA, Hayman SR, Short KD, Dispenzieri A, Kumar S, Zeldenrust SR, Greipp PR, Lust JA, Russell SJ, Buadi F, Kyle R, Fonseca R, Bergsagel L, Roy V, Mikhael JR, Stewart AK, Reeder CB, Dingli D, Allred J, Laumann K, Mandrekar S, Rajkumar SV.  Pomalidomide (CC4047) plus low dose dexamethasone (pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).  Blood. 2009 Nov 20; 114(22):178.
  39. Patel TA, Moreno-Aspitia A, Hume CB, Saurel C, Roy V, Perez EA.  A retrospective review of patients with adenoid cystic breast cancer treated at Mayo Clinic.  Cancer Res. 2009 Dec 15; 69(Suppl 3):610S.
  40. Buadi F, Dispenzieri A, Hayman S, Allred J, Laumann K, Roy V, Lacy M, Gertz M, Detweiler-Short K, Birgin A, Bergsagel L, Dingli D, Mikhael J, Reeder C, Stewart K, Zeldenrust S, Rajkumar SV, Kumar S.  A phase II trial of lenalidomide, cyclophosphamide and dexamethasone (RCD) in patients with primary amyloidosis. Amyloid. 2010 Apr; 17(Suppl 1):170-1.
  41. Dispenzieri A, Gertz MA, Hayman SR, Buadi F, Kumar SK, Reeder C, Zeldenrust SR, Rajkumar SV, Detweiler-Short K, Lust JA, Witzig TE, Kyle RA, Greipp PR, Russell SJ, Dingli D, Allred JB, Laumann K, Thompson M, Fonseca R, Bergsagel L, Stewart K, Mikhael J, Roy V, Lacy MQ. Pomalidomide and dexamethasone for previously treated AL: a phase 2 study.  Amyloid. 2010 Apr; 17(Suppl 1):87.
  42. Patel TA, Liu H, Hillman DW, Dueck AC, Ingle JN, Roy V, Hobday TJ, Northfelt DW, Perez EA, North Central.  Clinical characteristics, univariate, and multivariate Cox model analysis of long-term (> 3 years) survivors of stage IV metastatic breast cancer treated on phase II or III North Central Cancer Treatment Group (NCCTG) trials. [Abstract #1157].  J Clin Oncol. 2010 May 20; 28(15S):115s.
  43. Dispenzieri A, Abraham M, Hayman SR, Buadi F, Kumar S, Reeder CB, Mikhael JR, Zeldenrust S, Rajkumar SV, Short KD, Greipp PR, Russell SJ, Dingli D, Allred J, Laumann K, Fonseca R, Bergsagel PL, Roy V, Stewart K, Lacy M.  A phase-2 study of pomalidomide and dexamethasone in previously treated light chain (AL) amyloidosis. Blood. 2010 Nov 19; 116(21):434-5.
  44. Lacy M, Mandrekar S, Gertz MAA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Zeldenrust S, Dingli D, Greipp PR, Lust J, Russell S, Kyle R, Fonseca R, Bergsagel PL, Roy V, Stewart AK, Allred J, Laumann K, Reeder CB, Rajkumar SV, Mikhael JR.  Pomalidomide plus low dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide comparison of two dosing strategies in dual refractory disease.  Blood. 2010 Nov 19; 116(21):377. Abstract no. 863.
  45. Paulsen A, Malik S, Litzow MR, Gastineau D, Roy V, Solberg LA, Zubair A.  Dual roles  of CD8+t cell in hematopmetic progenitor cell mobilization and engraftment.  Blood. 2010 Nov 19; 116(21):157.
  46. Short KD, Rajkumar SV, Buadi F, Larson D, Hayman SR, Dispenzieri A, Gertz MAA, Kumar S, Mikhael JR, Roy V, Kyle R, Lacy M.  Increased incidence of extramedullary plasmacytomas in patients with multiple myeloma in the era of novel therapy and effect of pomalidomide on extramedullary disease.  Blood. 2010 Nov 19; 116(21):1256.
  47. Vishnu P, Paulsen A, Roy V, Zubair A.  Lenalidomide enhances clonogenic activity, proliferation and erythroid lineage commitment of CD34+progenitor cells while it is cytotoxic to CD34 accessory cells.  Blood. 2010 Nov 19; 116(21):509-10.
  48. Jiang L, Malik S, Litzow M, Gastineau D, Micallef I, Roy V, Solberg L, Zubair AC. CD34+cells from poor mobilizers are qualitatively equivalent to CD34+cells from good mobilizers.  Biol Blood Marrow Transplant. 2011 Feb; 17(Suppl 2):S204.
  49. Vishnu P, Roy V, Paulsen A, Zubair AC.  Efficacy and cost-benefit analysis of plerixafor plus filgrastim based on a risk adaptive approach for autologous peripheral blood hematopoietic progenitor cell collection.  Biol Blood Marrow Transplant. 2011 Feb; 17(Suppl 2):S197-8.
  50. J. Mikhael, V. Rajkumar, V. Roy, S. R. Hayman, R. Fonseca, K. Detweiler Short, B. LaPlant, K. M. Laumann, A. Dispenzieri, M. Lacy. Efficacy of pomalidomide plus low- dose dexamethasone in multiple myeloma patients despite previous use of lenalidomide. J Clin Oncol 29: 2011 (suppl; abstr 8067)
  51. Joseph R. Mikhael, MD  Morie A. Gertz, MD, Suzanne R. Hayman, MD,  Kristen Detweiler Short RN, CNP, Francis Buadi, MD, Angela Dispenzieri, MD,  Shaji Kumar, MD, Philip R. Greipp, MD,  John A. Lust, MD, PhD, Stephen J Russell, MD, PhD, David Dingli, MD., Steven Zeldenrust, MD, Rafael Fonseca, MD, P. Leif Bergsagel, MD, Vivek Roy, MD,   A. Keith Stewart, MD, Kristina Laumann, Betsy LaPlant MS., Craig Reeder, MD, S. Vincent Rajkumar, MD, Martha Q. Lacy, MD . Long Term Efficacy and Duration of Response of Pomalidamide in Patients with Relapsed Multiple Myeloma. International Myeloma Workshop (IMW) in Paris France. May 2011
  52. Wear S, Richardson PG, Revta C, Vij R, Fiala M, Lonial S, Mitchell AR, Siegel DS, Aleman A, Jakubowiak AJ, Durecki DE, Reece DE, Gul E, Chari A, Jagannath S, La L, Hofmeister CC, Bowers MA, Stewart AK, Hagerty R, Wolf JL, Pelle-Day G, Krishnan A, Duarte L, Zimmerman TM, Larsen D, Kumar S, Birgin A, Raje NS, Roy V, Mahara Mj, Fay JW, Messing T, Ott RF, Tasca L, Anderson KC, Giutsi K. The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development. Am Society of Hematology meeting 2011, Abstract 1024.
  53. MikhaeJR Hayman SR, Laumann K, Roy V, LaPlanT BR, Kumar S, Buadi FK, Reeder CR, Gertz MA, Dispenzieri A, Lust JA, Stewart AK, Russell S, Bergsagel PL, Dingli D, ZeldenrusT S, Fonseca R, Greipp PR, Hall RL, Rajkumar SV, LacY MQ. Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort. Am Society of Hematology meeting 2011, Abstract 2942
  54. Lacy MQ, LaPlant BR, Laumann K, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Kumar S, Lust JA, Russell S, Dingli D, Zeldenrust SR, Greipp PR, Fonseca R, Bergsagel PL, Roy V, Stewart AK, Reeder CB, Hall RL, Rajkumar SV, Mikhael JR. Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years. Am Society of Hematology meeting 2011, Abstract 3963
  55. Richardson PG, Berdeja JG, Niesvizky R, Lonial S, Roy V, Hari P, Berg D, Liu G, Gupta N, Di Bacco A, Hui A, Kumar, S.Oral weekly MLN9708, an investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma (MM): A phase I/II study.J Clin Oncol 30, 2012 (suppl; abstr 8033)
  56. Shaji K. Kumar, Betsy R. LaPlan, Wee Joo Chn, Jeffrey A. Zonder,Natalie Callande, Vivek Roy,  Briant Furt*, Charles Erlichman, and Keith Stewart. Phase 1/2 Trial of a Novel CDK Inhibitor Dinaciclib (SCH727965) in Patients with Relapsed Multiple Myeloma  emonstrates Encouraging Single Agent Activity. Am Society of Hematology meeting 2012, Abstract 76
  57. Steven R Schuster, Klaus Martin Kortuem, Yuan Xiao Zhu, Esteban Braggio, Chang-Xin Shi, Laura Bruins, Jessica Schmidt, Gregory Ahmann Shaji K. Kumar, S. Vincent Rajkumar, Joseph R. Mikhael, Vivek Roy, Betsy R. LaPlant, Kristina Laumann, Bart Barlogie, John D Shaughnessy Jr., Rafael Fonseca12, Leif Bergsagel, Martha Q Lacy and Keith Stewart. Cereblon Expression Predicts Response, Progression Free and Overall Survival After Pomalidomide and Dexamethasone Therapy in Multiple Myeloma Am Society of Hematology meeting 2012, Abstract 194
  58. Martha Q Lacy, Shaji K. Kumar, Betsy R. LaPlant, Kristina Laumann, Morie A Gertz, Suzanne R Hayman, Francis K Buadi, Angela Dispenzieri,John A. Lust, Stephen Russell, David Dingli, Steven R Zeldenrust, Rafael Fonseca, P.Leif Bergsagel, Keith Stewart, Vivek Roy, Taimur Sher, Asher Chanan-Khan, Craig Reeder, S. Vincent Rajkumar and Joseph R. Mikhael. Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicing Outcome in 345 Patients Am Society of Hematology meeting 2012, Abstract 201
  59. Shaji K. Kumar, Jesus G. Berdeja, Ruben Niesvizky, Sagar Lonial, Mehdi Hamadani, A. Keith Stewart, Vivek Roy, Parameswaran Hari, Robert Vescio, Deborah Berg, Jianchang Lin, Alessandra Di Bacco, Neeraj Gupta, Ai-Min Hui, and Paul G. Richardson. A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM) Am Society of Hematology meeting 2012, Abstract 332
  60. Veena Devi Salem Fauble, James L Slack, William Hogan, Vivek Roy, , Jose Leis, Amylou C. Dueck, Mark R Litzow, Mrinal M. Patnaik, Pardanani Animesh, Candido E. Rivera, Raoul Tibes, John Camoriano, Roberta H. Adams, Pierre Noel, Nandita Khera, Lisa Sproat, and Ruben A. Mesa. Allogeniec Stem Cell Transplantation for Primary and Post ET/PV Myelofibrosis At Mayo Clinic: A Retrospective Review Across a Geographically Diverse 3 Site Cancer Center. Am Society of Hematology meeting 2012, Abstract 2850
  61. Shaji K. Kumar, Amrita Krishnan, Vivek Roy, Todd M Zimmerman, Morie Abraham A Gertz, Keith E. Stockerl-Goldstein, Francis K Buadi, Cara Rosenbaum, Ann Birgin, Mark Fiala, Valeria Jiminez, Michele Maharaj, Michael N. Needle and Ravi Vij, Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of Bendamustine in Combination with Lenalidomide and Dexamethasone (BRD) in Patients with Relapsed Multiple Myeloma: A Multiple Myeloma Research Consortium Study. Am Society of Hematology meeting 2012, Abstract 2965
  62. Swati Andhavarapu, Abba Zubair, Vivek Roy. Effect of Body Mass Index On the Mobilizing Efficacy of Plerixafor in Patients Undergoing Autologous Stem Cell Collection: A Retrospective Study. BIol Blood Marrow Transplant 2013 Feb; 19(2, suppl):Abstract 129
  63. P Richardson, J Berdeja, R Niesvizky, S Lonial, M Hamadani, A Stewart, P Hari, R Vescio, V Roy, D Berg, J Lin, A Hui, S Kumar. Weekly oral investigational proteasome inhibitor MLN9708 plus lenalidomide-dexamethasone in elderly patients (Pts) with previously untreated multiple myeloma (MM): subset analysis of a phase 1/2 study. 18th Congress of the European Hematology Association, June 13–16, 2013. Haematologica June 2013 98: Abstract P236
  64. Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials. Preet Paul Singh, Shaji K Kumar, Betsy R. LaPlant*, Morie A Gertz, Angela Dispenzieri, P. Leif Bergsage, Martha Q Lacy, Siddharth Singh, Vivek Roy, Francis K Buadi, David Dingli, Robert Kyle, S. Vincent Rajkumar, and Prashant Kapoor Am Society of Hematology meeting 2013. Abstract 407
  65. Financial Burden In Recipients Of Allogeneic Hematopoietic Cell Transplantation Nandita Khera, Yu-hui Chang, Shahrukh K Hashmi, James L Slack, Veena Fauble, Timothy Beebe, , Vivek Roy, Lisa Sproat, Jose F. Leis, Pierre Noel, Jon Tilburt, and Joseph R. Mikhael Am Society of Hematology meeting 2013, DEC 2013. Abstract 721
  66. Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients Kevin R. Kelly, Asher Chanan-Khan, George Somlo, Leonard T Heffner, David S Siegel, Todd M Zimmerman, Sundar Jagannath, Nikhil C. Munshi, Sagar Lonial, Vivek Roy, Markus Ruehle, Shailesh Chavan, Pankaj PatelMarkus RothenburgerAndrea Wartenberg-Demand, Thomas Haeder, and Kenneth C. Anderson Am Society of Hematology meeting 2013, DEC 2013. Abstract 758
  67. Inhibition Of The Deubiquitinating Enzymes UCHL5 and USP14  Is Lethal To Waldenströms Macroglobulinemia Cells Kasyapa S. Chitta, Aneel Paulus, Sharoon Akhtar, Maja Kuranz, Vivek Roy, Stephen M Ansell, Anne J. Novak, Peter Martin, Richard R. Furman, Morton Coleman, Stig Linder, and Asher Chanan-Khan, MD Am Society of Hematology meeting 2013, DEC 2013. Abstract 1823
  68. Interference Of The Tumor Supportive Effects Of BCL2 and MCL1 Sensitize Malignant Plasma Cells To The Lethal Effects Of Lenalidomide and Dexamethasone Regimen: An Important Clinical Path For BCL2 Targeting Drugs Aneel Paulus, Kasyapa S. Chitta, Sharoon Akhtar, Maja Kuranz, Shaji Kumar, Vivek Roy, Stephen M Ansell, Joseph R. Mikhael, Angela Dispenzieri, Craig Reeder, Candido E. Rivera, James M. Foran, Francis Buadi, Vincent Rajkumar, and Asher Chanan-Khan, MD Am Society of Hematology meeting 2013, DEC 2013. Abstract 1928
  69. A Phase I/II Trial Of Pomalidomide, Bortezomib and Dexamethasone In Patients With Relpased Or Refractory Multiple Myeloma Joseph R. Mikhael, , Vivek RoyPaul G. Richardson, Andrzej Jakubowiak, Kristina Laumann, Betsy R. LaPlant, Angela DispenzieriS. Vincent Rajkumar, Rafael Fonseca, Nelson Leung, Francis Buadi, P. Leif Bergsagel, Robert Kyle, Thomas E. Witzig10*, Craig Reeder, John A LustStephen Russell, Suzanne R Hayman, Shaji K Kumar, David Dingli, Stephen M Ansell, Robert Dalton, Yi Lin, Taimur Sher, Prashant Kapoor, Arleigh McCurdy, Asher Chanan-Khan, A. Keith Stewart, Morie A Gertz, and Martha Q Lacy Am Society of Hematology meeting 2013, DEC 2013. Abstract 1940
  70. Phase 2 Trial Of Single Agent MLN9708 In Patients With Relapsed Multiple Myeloma Not Refractory To Bortezomib Shaji K Kumar, Vivek Roy, Craig Reeder, Betsy R. LaPlant, Martha Q Lacy, Morie A Gertz, Kristina Laumann, Melanie Ann Thompson, Thomas E Witzig, Francis K Buadi, Candido E. Rivera, Joseph R. Mikhael, Peter Leif Bergsagel, Lisa Hwa, S. Vincent Rajkumar, and Angela Dispenzieri Am Society of Hematology meeting 2013, DEC 2013. Abstract 1944
  71. Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma Yi Lisa Hwa, Kristina M Laumann, Betsy R LaPlant, Francis Buadi, David Dingli, Angela Dispenzieri, Morie A Gertz, Ronald S. GoSuzanne R HaymanPrashant Kapoor, Shaji K Kumar, Nelson Leung, Yi Lin, John A Lust, Arleigh McCurdy, Joseph Mikhael, Vivek Roy, Stephen Russell, Steven R Zeldenrust, S. Vincent Rajkumar,  and Martha Q Lacy. Am Society of Hematology meeting 2013, DEC 2013. Abstract 1979
  72. Development Of a Human IgM Secreting Model Of Rpci-WM1 Through Xenografting In SCID Mice For In Vivo Drug EvaluationKasyapa S. Chitta, Aneel Paulus, Sharoon Akhtar, Maja Kuranz, Sikander Ailawadhi,  Kena Miller, Candido E. Rivera, Gerardo Colon-Otero, Vivek Roy, Stephen M Ansell, Anne J. Novak, Peter Martin, Morton Coleman, and Asher Chanan-Khan, Am Society of Hematology meeting 2013, DEC 2013. Abstract 3081
  73. The Novel Proteasome Inhibitor MLN2238 (Ixazomib) Induces Death In CLL Cells In Vitro and Potentiates Lethality Of Fludarabine and The BCL2 Inhibitor At-101 Kasyapa S. Chitta, Aneel Paulus, Sharoon Akhtar, Maja Kuranz, Kena Miller, Candido E. Rivera, Vivek Roy, James M. Foran, Aisha Masood, and Asher Chanan-Khan. Am Society of Hematology meeting 2013, DEC 2013. Abstract 4189
  74. The Deubiquitinating Enzymes Of The 19S Proteasome Offer Novel Therapeutic Opportunity In Bortezomib Resistant Waldenströms Macroglobulinemia Aneel Paulus, Kasyapa S. Chitta, Sharoon Akhtar, Maja Kuranz, Vivek Roy, Stephen M Ansell, Anne J. Novak, Peter Martin, Richard R. Furman, Morton Coleman, Stig Linder, and Asher Chanan-Khan. Am Society of Hematology meeting 2013, Dec 2013. Abstract 4426
Book Chapters
  1. Roy V, Wiesdorf D. Typical and atypical mycobacterial infections in transplant recipients. In:  Bowden RA, Ljungman P, Paya CV, editors. Transplant Infections. Philadelphia: Lippincott-Raven; 1998. p. 195-202.  (Book chapter)
  2. Roy V, Perez EA.  Breast cancer. In: Waldman SA, Terzic A, editors. Pharmacology and therapeutics: principles to practice. Philadelphia: Saunders/Elsevier; 2009. p. 933-44. (Book chapter)
  3. Anthony J. Charles, Vivek Roy, Edith A. Perez. Adjuvant therapy in Breast Cancer. In: Howard Silberman and Allan W. Silberman, Editors. Principles and Practice of Surgical Oncology. Philadelphia, PA. Lippincott Williams and Wilkins; 2010. p 397-415
  4. Vivek Roy and Phillip R. Greipp. Staging of Multiple Myeloma. In: Morie A. Gertz and S Vincent Rajkumar, Editors. Multiple Myeloma. Diagnosis and Treatment. Springer 2013. P 47-54.
  5. Prakash Vishnu and Vivek Roy. Clinical Experience with Nanoparticle Albumin Bound (Nab) Paclitaxel.  In: Vladimir Torchilin, Editor. Frontiers in Nanomedicine research – Vol II. World Scientific Publishing (Publication pending)
Editorials
  1. Roy V, Perez EA.  Adjuvant docetaxel plus doxorubicin and cyclophosphamide increases survival compared with fluorouracil plus doxorubicin and cyclophosphamide in women with operable node-positive breast cancer.  Cancer Treat Rev 2006 Feb; 32(1):55-8.
  2. Roy V.  Crucial role of laboratory tests in modern medicine.  Am J Med. 2008 Sep; 121(9):e27, author reply e29.
  3. Roy V.  Commentary.  Clin Chem. 2010 Jun; 56(6):895-6.
Peer-Reviewed Articles
  1. Roy V, Tillyer ML, Colvin BT.  Acute abdominal pain due to an acquired disorder of coagulation.  Br Med J (Clin Res Ed) 1988 May 21; 296(6634):1460.
  2. Roy V, Newland AC.  Raynaud's phenomenon and cryoglobulinaemia associated with the use of recombinant human alpha-interferon. Lancet. 1988 Apr 23; 1(8591):944-5-.
  3. Roy V, Gutteridge CN, Nysenbaum A, Newland AC.  Combination chemotherapy with conservative obstetric management in the treatment of pregnant patients with acute myeloblastic leukaemia.  Clinical & Laboratory Haematology. 1989; 11(3):171-8.
  4. Roy V, Veys P, Jackson F, Ryan J, Lowdell M, Newland AC.  Adult respiratory syndrome following autologous bone marrow transfusion.  Bone Marrow Transplant. 1989 Nov; 4(6):711-2.
  5. Roy V, Verfaillie CM.  Refractory thrombocytopenia due to anti-PLA1 antibodies following autologous peripheral blood stem cell transplantation: case report and review of literature.  Bone Marrow Transplant. 1996 Jan; 17(1):115-7.
  6. Verfaillie CM, Bhatia R, Miller W, Mortari F, Roy V, Burger S, McCullough J, Stieglbauer K, Dewald G, Heimfeld S, Miller JS, McGlave PB.  BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early- chronic phase but not accelerated-phase chronic myelogenous leukemia patients. Blood. 1996 Jun 1; 87(11):4770-9.
  7. Roy V, Weisdorf D.  Mycobacterial infections following bone marrow transplantation: a 20 year retrospective review.  Bone Marrow Transplant. 1997 Mar; 19(5):467-70.
  8. Roy V, Miller JS, Verfaillie CM.  Phenotypic and functional characterization of committed and primitive myeloid and lymphoid hematopoietic precursors in human fetal liver.  Exp Hematol. 1997 May; 25(5):387-94.
  9. Roy V, Ochs L, Weisdorf D.  Late infections following allogeneic bone marrow transplantation: suggested strategies for prophylaxis.  Leukemia & Lymphoma. 1997 Jun; 26(1-2):1-15.
  10. Roy V, Verfaillie CM.  Soluble factor(s) produced by adult bone marrow stroma inhibit in vitro proliferation and differentiation of fetal liver BFU-E by inducing apoptosis.  J Clin Invest. 1997 Aug 15; 100(4):912-20.
  11. Mandanas RA, Carter TH, Epstein RB, Roy V, Selby GB.  Marrow and stem cell transplantation in Oklahoma: fifteen years of experience and results.  J Okla State Med Assoc. 1998 Sep; 91(6):339-46.
  12. Roy V, Verfaillie CM.  Expression and function of cell adhesion molecules on fetal liver, cord blood and bone marrow hematopoietic progenitors: implications for anatomical localization and developmental stage specific regulation of hematopoiesis.  Exp Hematol. 1999 Feb; 27(2):302-12.
  13. Roy V, Hammerschmidt DE.  Disseminated histoplasmosis following prolonged low-dose methotrexate therapy.  Am J Hematol. 2000 Jan; 63(1):59-60.
  14. Abang AM, Takemoto MH, Pham T, Mandanas RA, Roy V, Selby GB, Carter TH. Efficacy and safety of oral granisetron versus i.v. granisetron in patients undergoing peripheral blood progenitor cell and bone marrow transplantation.  Anticancer Drugs. 2000 Feb; 11(2):137-42.
  15. Fisher RI, Dana BW, LeBlanc M, Kjeldsberg C, Forman JD, Unger JM, Balcerzak SP, Gaynor ER, Roy V, Miller T.  Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.  J Clin Oncol. 2000 May; 18(10):2010-6.
  16. Roy V, Ali LI, Selby GB. Routine chest radiography for the evaluation of febrile neutropenic patients after autologous stem cell transplantation.  Am J Hematol. 2000 Jul; 64(3):170-4.
  17. Roy V, Ali LI, Carter TH, Selby GB.  Successful non-surgical treatment of disseminated polymicrobial fungal infection in a patient with pancytopenia and graft-versus-host disease.  J Infect. 2000 Nov; 41(3):273-5.
  18. Petersdorf SH, Kopecky KJ, Head DR, Boldt DH, Balcerzak SP, Wun T, Roy V, Veith RW, Appelbaum FR.  Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study.  Leukemia. 2001 Feb; 15(2):208-16.
  19. Roy V, Rizvi MA, Vesely SK, George JN. Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes.  Bone Marrow Transplant. 2001 Mar; 27(6):641-6.
  20. Selby GB, Ali LI, Carter TH, Veseley S, Roy V. The influence of health insurance on outcomes of related-donor hematopoietic stem cell transplantation for AML and CML. Biol Blood Marrow Transplant. 2001; 7(10):576.
  21. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.  N Engl J Med. 2001 Dec 6; 345(23):1655-9.
  22. Whitehead RP, Lew D, Flanigan RC, Weiss GR, Roy V, Glode ML, Dakhil SR, Crawford ED.  Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a Southwest Oncology Group study.  J Immunother. 2002 Jul-Aug; 25(4):352-8.
  23. Dispenzieri A, Moreno-Aspitia A, Suarez GA, Lacy MQ, Colon-Otero G, Tefferi A, Litzow MR, Roy V, Hogan WJ, Kyle RA, Gertz MA.  Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome: and a review of the literature.  Blood. 2004 Nov 15; 104(10):3400-7.
  24. Roy V, Perez WS, Eapen M, Marsh JCW, Pasquini M, Pasquini R, Mustafa MM, Bredeson CN.  Bone marrow transplantation for Diamond-Blackfan anemia.  Biol Blood Marrow Transplant. 2005 Aug; 11(8):600-8.
  25. Pavletic SZ, Khouri IF, Haagenson M, King RJ, Bierman PJ, Bishop MR, Carston M, Giralt S, Molina A, Copelan EA, Ringden O, Roy V, Ballen K, Adkins DR, McCarthy P, Weisdorf D, Montserrat E, Anasetti C.  Unrelated donor marrow transplantation for B- Cell chronic lymphocytic leukemia after using myeloablative conditioning: Results from the center for international blood and marrow transplant research.  J Clin Oncol. 2005 Aug 20; 23(24):5788-94.
  26. Roy A, Gisel JJ, Roy V, Bouras EP.  Superior mesenteric artery (Wilkie's) syndrome as a result of cardiac cachexia.  J Gen Intern Med. 2005 Oct; 20(10):C3-4.
  27. Roy A, Roy V.  Using beta-blockers to cut perioperative risk in CAD. Cardioprotective strategies for noncardiac surgery.  Postgrad Med. 2005 Dec; 118(6):34-6, 41-2.
  28. Roy A, Roy V.  Using beta-blocker to cut perioperative risk in CAD. [Turkish]. SENDROM. 2006; 18(12):42-5.
  29. Roy A, Heckman MG, Roy V.  Associations between the hospitalist model of care and quality-of-care-related outcomes in patients undergoing hip fracture surgery.  Mayo Clin Proc. 2006 Jan; 81(1):28-31.
  30. Roy V, Perez EA.  Adjuvant docetaxel plus doxorubicin and cyclophosphamide increases survival compared with fluorouracil plus doxorubicin and cyclophosphamide in women with operable node-positive breast cancer.  Cancer Treat Rev. 2006 Feb; 32(1):55-8. Epub 2006 Jan 19.
  31. Sekhon SS, Roy V. Thrombocytopenia in adults: A practical approach to evaluation and management.  South Med J. 2006 May; 99(5):491-8; quiz 499-500, 533.
  32. Roy A, Roy V.  Primary systemic amyloidosis. Early diagnosis and therapy can improve survival rates and quality of life.  Postgrad Med. 2006 Jun-Jul; 119(1):93-9.
  33. Roy V, Perez EA.  New therapies in the treatment of breast cancer.  Semin Oncol. 2006 Jun; 33(3 Suppl 9):S3-8.
  34. Valente M, Roy V, Lacy MQ, Dispenzieri A, Gertz MA.  Autologous stem cell transplantation and IgM amyloidosis.  Leuk Lymphoma. 2006 Jun; 47(6):1006-12.
  35. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.  Mayo Clin Proc. 2006 Aug; 81(8):1047-53.
  36. Roy A, Roy V.  Primary systemic amyloidosis. [Turkish].  SENDROM. 2007; 19(1):62-7.
  37. Roy A, Roy V.  An unusual case of prochlorperazine induced dyskinesia masquerading as stroke.  Resident & Staff Physicians. 2007 Feb; 53(2):45-6.
  38. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB, Lust JA, Russell SJ, Hayman SR, Roy V, Kumar S, Zeldenrust SR, Dalton RJ, Stewart AK. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement.  Mayo Clin Proc. 2007 Mar; 82(3):323-41.
  39. Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, Kumar S, Lacy MQ, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Reeder CB, Roy V, Kyle RA, Rajkumar SV, Fonseca R.  A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.  Leukemia. 2007 Mar; 21(3):529-34. Epub 2007 Jan 18.
  40. Amar S, Roy V, Perez EA.  Letrozole: present and future role in the treatment of breast cancer.  Expert Opin Pharmacother. 2007 Aug; 8(12):1965-75.
  41. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, Litzow MR, Fonseca R, Roy V, Rajkumar SV, Gertz MA.  Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.  Leukemia. 2007 Sep; 21(9):2035-42. Epub 2007 Jun 21.
  42. Zubair AC, Grant R, Wu W, Tun H, Rivera C, Moreno-Aspitia A, Joyce M, Roy V, Colon- Otero G, Solberg LA.  Platelet count is a sensitive predictor of autologous peripheral blood progenitor cell collection yield in previously treated plasma cell disease patients. Transfusion. 2008 Jun; 48(6):1106-14. Epub 2008 Feb 25.
  43. Roy V.  Artifactual laboratory abnormalities in patients with paraproteinemia.  South Med J. 2009 Feb; 102(2):167-70.
  44. Roy V, LaPlant BR, Gross GG, Bane CL, Palmieri FM, North Central Cancer Treatment Group.  Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab- paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).  Ann Oncol. 2009 Mar; 20(3):449-53. Epub 2008 Dec 15.
  45. Amar S, Roy V, Perez EA.  Treatment of metastatic breast cancer: looking towards the future.  Breast Cancer Res Treat. 2009 Apr; 114(3):413-22. Epub 2008 May 09.
  46. Roy V, Perez EA.  Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways.  Breast Cancer Res Treat. 2009 Jul; 116(1):31-8. Epub 2008 Dec 20.
  47. Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, Dispenzieri A, Buadi F, Bergsagel PL, Gertz MA, Dalton RJ, Mikhael JR, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Stewart AK, Kyle RA, Greipp PR, Rajkumar SV. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone.  Blood. 2009 Jul 16; 114(3):518 21. Epub 2009 Mar 26.
  48. Hari PN, Zhang MJ, Roy V, Perez WS, Bashey A, To LB, Elfenbein G, Freytes CO, Gale RP, Gibson J, Kyle RA, Lazarus HM, McCarthy PL, Milone GA, Pavlovsky S, Reece DE, Schiller G, Vela-Ojeda J, Weisdorf D, Vesole D.  Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant.  Leukemia. 2009 Aug; 23(8):1528-34. Epub 2009 Mar 26.
  49. Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J, Wu W, Laumann K, Espinoza-Delgado I, Gore SD, Mayo P2C Phase II Consortium.  A phase 2 study of vorinostat in acute myeloid leukemia.  Haematologica. 2009 Oct; 94(10):1375- 82.
  50. Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV.  Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.  J Clin Oncol. 2009 Oct 20; 27(30):5008-14. Epub 2009 Aug 31.
  51. Roy V, Perez EA.  Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. Oncologist. 2009 Nov; 14(11):1061-9. Epub 2009 Nov 03.
  52. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Greipp PR, Hayman SR, Kyle RA, Lacy MQ, Lust JA, Reeder CB, Roy V, Russell SJ, Short KE, Stewart AK, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Bergsagel PL. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc. 2009 Dec; 84(12):1095-110.
  53. Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy Conflicts of interest, authorship, and disclosures in industry-related scientific publications.  Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4.
  54. Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, Kumar S, Dispenzieri A, Mikhael JR, Bergsagel PL, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Rajkumar SV.  Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.  Blood. 2010 Feb 18; 115(7):1343-50. Epub 2009 Dec 11.
  55. Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ, Cervantes F, Devine SM, Gale RP, Gupta V, Hahn TE, Hogan WJ, Kroger N, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Schiller G, Schouten HC, Roy V, Wiernik PH, Horowitz MM, Giralt SA, Arora M. Outcome of transplantation for myelofibrosis.  Biol Blood Marrow Transplant. 2010 Mar; 16(3):358-67. Epub 2009 Oct 30.
  56. Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, Micallef IN, Porrata LF, Ansell SM, Reeder CB, Roy V, Witzig TE.  A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.  Am J Hematol. 2010 May; 85(5):320-4.
  57. Vishnu P, Roy V.  nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer. Womens Health (Lond Engl). 2010 Jul; 6(4):495-506.
  58. Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, Bergsagel PL, Buadi FK, Colgan JP, Dingli D, Dispenzieri A, Greipp PR, Habermann TM, Hayman SR, Inwards DJ, Johnston PB, Kumar SK, Lacy MQ, Lust JA, Markovic SN, Micallef IN, Nowakowski GS, Porrata LF, Roy V, Russell SJ, Short KE, Stewart AK, Thompson CA, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Gertz MA. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.  Mayo Clin Proc. 2010 Sep; 85(9):824-33. Epub 2010 Aug 11.
  59. Bhatt V, Vendrell N, Nau K, Crumb D, Roy V.  Implementation of a standardized protocol for prevention and management of oral mucositis in patients undergoing hematopoietic cell transplantation.  J Oncol Pharm Pract. 2010 Sep; 16(3):195-204. Epub 2009 Nov 12.
  60. Gay F, Rajkumar SV, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ, Chen-Kiang S, Roy V, Jayabalan DS, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Niesvizky R.  Clarithromycin (Biaxin)-lenalidomide- low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.  Am J Hematol. 2010 Sep; 85(9):664-9.
  61. Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV, Buadi F. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).  Leukemia. 2010 Nov; 24(11):1934-9. Epub 2010 Sep 09.
  62. Reece DE, Vesole DH, Shrestha S, Zhang MJ, Perez WS, Dispenzieri A, Milone GA, Abidi M, Atkins H, Bashey A, Bredeson CN, Boza WB, Freytes CO, Gale RP, Gajewski JL, Gibson J, Hale GA, Kumar S, Kyle RA, Lazarus HM, McCarthy PL, Pavlovsky S, Roy V, Weisdorf DJ, Wiernik PH, Hari PN. Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study.  Clin Lymphoma Myeloma Leuk. 2010 Dec; 10(6):458-63.
  63. Vishnu P, Roy V.  Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer.  Breast Cancer (Auckl). 2011; 5:53-65. Epub 2011 Apr 13.
  64. Vogl DT, Wang T, Perez WS, Stadtmauer EA, Heitjan DF, Lazarus HM, Kyle RA, Kamble R, Weisdorf D, Roy V, Gibson J, Ballen K, Holmberg L, Bashey A, McCarthy PL, Freytes C, Maharaj D, Maiolino A, Vesole D, Hari P.  Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2011; 17(12):1765-74.
  65. Kapoor P, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Dingli D, Mikhael JR, Roy V, Kyle RA, Greipp PR, Kumar S, Mandrekar SJ.  Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis.  Leukemia. 2011 Apr; 25(4):689-96. Epub 2011 Jan 14.
  66. Adkisson CD, Vallow LA, Kowalchik K, McNeil R, Hines S, Deperi E, Moreno A, Roy V, Perez EA, McLaughlin SA.  Patient age and preoperative breast MRI in women with breast cancer: biopsy and surgical implications. Ann Surg Oncol. 2011 Jun; 18(6):1678- 83. Epub 2011 Jan 05.
  67. Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A, Gertz M, Kumar S, Mikhael J, Roy V, Kyle RA, Lacy MQ. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma.  Leukemia. 2011 Jun; 25(6):906-8. Epub 2011 Feb 25.
  68. Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Stewart AK, Laumann K, Mandrekar SJ, Reeder C, Rajkumar SV, Mikhael JR. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.  Blood. 2011 Sep 15; 118(11):2970-5. Epub 2011 Jun 20.
  69. Reinholz MM, Kitzmann KA, Tenner K, Hillman D, Dueck AC, Hobday TJ, Northfelt DW, Moreno-Aspitia A, Roy V, LaPlant B, Allred JB, Stella PJ, Lingle WL, Perez EA. Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437.  Clin Cancer Res. 2011 Nov 15; 17(22):7183-93. Epub 2011 Oct 05.
  70. Vishnu P, Roy V, Paulsen A, Zubair AC.  Efficacy and cost-benefit analysis of risk- adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion. 2012 Jan; 52(1):55-62. Epub 2011 Jun 09.
  71. Gertz M A, Buadi FK, Hayman SR, Dingli D, Dispenzieri A. Greipp PR, Kumar SK, Lacy MQ, Lust JA, Leung N, Rajkumar SV, Russell SJ, Zeldenrust SR, Mikhael JR, Roy V, Kyle RA. Immunoglobulin D amyloidosis: a distinct entity. Blood 2012;119:44-8.
  72. Jiang L, Malik S, Litzow M, Gastineau D, Micallef I, Roy V, Solberg L, Zubair AC. Hematopoietic stem cells from poor and good mobilizers are qualitatively equivalent. Transfusion 2012;52:542-8.
  73. Kumar SK, Hayman SR, Buadi FK, Roy V, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood 2012;119:4860-7.
  74. Roy V. Autologous stem cell transplant for Al amyloidosis. Bone Marrow Res 2012;2012:238961
  75. Roy V, Pockaj BA, Allred JB, et al. A Phase II Trial of Docetaxel and Carboplatin Administered Every 2 Weeks as Preoperative Therapy for Stage II or III Breast Cancer: NCCTG Study N0338. Am J Clin Oncol 2012.
  76. Sluzevich JC, Hall MR, Roy V. Subcutaneous panniculitis-like T-cell lymphoma after rituximab. J Am Acad Dermatol 2012;67:e223-5.
  77. Vishnu P, Roy V, Paulsen A, Zubair AC. Efficacy and cost-benefit analysis of risk- adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion 2012;52:55-62.
  78. Witzig TE, Laumann KM, Lacy MQ, et al. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia 2013; 27(1):220-5.
  79. Andhavarapu S, Roy V. Immunomodulatory drugs in multiple myeloma. Expert Rev Hematol. 2013 Feb; 6(1):69-82. PMID:23373782. DOI:10.1586/ehm.12.62.
  80. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart K, Rajkumar SV, Chanan-Khan A, Lacy MQ. Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk- Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clin Proc. 2013 Apr; 88(4):360-76.
  81. Larsen JT, Hogan WJ, Micallef IN, Dispenzieri A, Gertz MA, Inwards DJ, Tun HW, Roy V, Geyer SM, Allred JB, Wu W, Ansell SM, Elliott MA, Tefferi A, Porrata LF, Gastineau DA, Lacy MQ, Litzow MR. A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin. Leuk Lymphoma. 2013 Aug; 54(8):1713-8. Epub 2012 Dec 31.
  82. Michaelis LC, Saad A, …, Roy V, ..et al. Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research. Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant. 2013 May; 19(5):760-6.
  83. Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, Roy V, Buadi F, Dingli D, Hayman SR, Leung N, Lin Y, Mikhael J, Kumar SK. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood. 2013 Oct 21. PMID:24144641
  84. Copelan, EA., Hamilton BK,,…..Roy V,.. et al. (2013). "Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI." Blood 2013 122(24): 3863- 3870
  85. Paulus A, Chitta K, Akhtar S, Personett D, Miller KC, Thompson KJ, Carr J, Kumar S, Roy V, Ansell SM, Mikhael JR, Dispenzieri A, Reeder CB, Rivera CE, Foran J, Chanan- Khan A. AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenstrom macroglobulinaemia. Br J Haematol. 164 (3):352-65. PMID:24236538 .
  86. Khera N, Chang YH, Hashmi S, Slack J, Beebe T, Roy V, et al. Financial Burden in Recipients of Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2014. ePublish 5/29/2014

 

 

 

Vivek Roy

Associate Professor

 

  • : 904-953-7291
    Fax: 904-953-2315
  • DEPARTMENTDepartment of Internal Medicine
    Mayo Clinic, Jacksonville
    Florida
  • COUNTRY USA